Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Augment Bone Graft
- Development stage
- Unknown
- Lead developer
- Wright Medical Group
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Augment Bone Graft is a combination product consisting of recombinant human platelet-derived growth factor BB (rhPDGF-BB) and a synthetic bone scaffold, beta-tricalcium phosphate (beta-TCP). It is indicated as an alternative to autologous bone graft (autograft) for use in hindfoot and ankle fusion procedures. The rhPDGF-BB component, also known as becaplermin, is a potent chemotactic and mitogenic agent that recruits and stimulates the proliferation of osteoblasts and mesenchymal stem cells, while the beta-TCP provides an osteoconductive scaffold for new bone formation. Originally developed by BioMimetic Therapeutics, the product was acquired by Wright Medical Group and is currently part of the Stryker portfolio following Stryker's acquisition of Wright Medical. It received FDA Premarket Approval (PMA) in 2015.
- Brand names
- Augment Bone Graft
- Other names
- rhPDGF-BB/beta-TCP
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on Augment Bone Graft.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Augment Bone Graft.